| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.095 | 0.003 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.004 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.088 | 0.007 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.007 |